Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7403
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor ; volume:19 ; number:5 ; day:27 ; month:6 ; year:2015 ; pages:544-546 ; date:10.2016
Pituitary ; 19, Heft 5 (27.6.2015), 544-546, 10.2016
- Urheber
-
Aylwin, Simon J. B.
- Beteiligte Personen und Organisationen
-
Bodi, Istvan
Beaney, Ronald
SpringerLink (Online service)
- DOI
-
10.1007/s11102-015-0663-4
- URN
-
urn:nbn:de:1111-2016092110349
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aylwin, Simon J. B.
- Bodi, Istvan
- Beaney, Ronald
- SpringerLink (Online service)
Ähnliche Objekte (12)
Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
Craniopharyngioma
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Craniopharyngioma : surgical treatment
Obesity and craniopharyngioma
Craniopharyngioma in Adults
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
Craniopharyngioma
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Craniopharyngioma : surgical treatment
Obesity and craniopharyngioma
Craniopharyngioma in Adults
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
Craniopharyngioma
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Craniopharyngioma : surgical treatment
Obesity and craniopharyngioma
Craniopharyngioma in Adults
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors